Nayzilam (Midazolam) Patent Expiration, LOE Window & CMS Spending
Nayzilam (Midazolam) by Ucb: FDA Orange Book LOE 2028-01-18, 0 AB generics, $115.9M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ucb |
| FDA Application & Pathway | N211321 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2028-01-18 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $115.9M |
| 2024 Medicare Part D Spend | $36.9M |
| 2024 Medicaid Spend | $79.0M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 18.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.